Concepts (301)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy Complications, Infectious | 25 | 2025 | 117 | 4.860 |
Why?
|
| HIV Infections | 45 | 2025 | 2586 | 2.730 |
Why?
|
| Infectious Disease Transmission, Vertical | 12 | 2021 | 74 | 1.600 |
Why?
|
| Microcephaly | 4 | 2025 | 21 | 1.500 |
Why?
|
| Anti-HIV Agents | 16 | 2025 | 486 | 1.430 |
Why?
|
| Congenital Abnormalities | 2 | 2019 | 21 | 1.190 |
Why?
|
| Puerto Rico | 21 | 2025 | 1413 | 1.190 |
Why?
|
| Pregnancy | 31 | 2025 | 1772 | 1.110 |
Why?
|
| HIV-1 | 17 | 2025 | 755 | 0.900 |
Why?
|
| Pregnancy Outcome | 7 | 2025 | 102 | 0.880 |
Why?
|
| Vaccines | 1 | 2024 | 65 | 0.780 |
Why?
|
| Ritonavir | 6 | 2020 | 15 | 0.740 |
Why?
|
| Female | 61 | 2026 | 24698 | 0.730 |
Why?
|
| Cyclonic Storms | 3 | 2021 | 80 | 0.680 |
Why?
|
| Syphilis | 1 | 2021 | 24 | 0.670 |
Why?
|
| Infant, Newborn | 14 | 2025 | 972 | 0.670 |
Why?
|
| Humans | 65 | 2026 | 43102 | 0.630 |
Why?
|
| Brain | 4 | 2025 | 1472 | 0.610 |
Why?
|
| Health Personnel | 2 | 2025 | 277 | 0.600 |
Why?
|
| Adult | 41 | 2026 | 13872 | 0.600 |
Why?
|
| Pregnancy Complications | 2 | 2019 | 140 | 0.590 |
Why?
|
| Adaptation, Psychological | 3 | 2021 | 420 | 0.580 |
Why?
|
| AIDS Vaccines | 5 | 2013 | 26 | 0.570 |
Why?
|
| Hospitals, University | 1 | 2017 | 39 | 0.540 |
Why?
|
| Disasters | 1 | 2017 | 79 | 0.490 |
Why?
|
| Social Support | 2 | 2017 | 445 | 0.480 |
Why?
|
| Health Policy | 2 | 2021 | 184 | 0.480 |
Why?
|
| Reverse Transcriptase Inhibitors | 3 | 2017 | 57 | 0.470 |
Why?
|
| Prospective Studies | 11 | 2025 | 1600 | 0.460 |
Why?
|
| Family | 1 | 2015 | 195 | 0.430 |
Why?
|
| Desogestrel | 3 | 2025 | 5 | 0.430 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2015 | 24 | 0.420 |
Why?
|
| Influenza Vaccines | 2 | 2015 | 58 | 0.400 |
Why?
|
| Benzoxazines | 3 | 2020 | 47 | 0.400 |
Why?
|
| Caregivers | 1 | 2015 | 197 | 0.390 |
Why?
|
| Prejudice | 2 | 2010 | 116 | 0.380 |
Why?
|
| Public Health | 2 | 2018 | 424 | 0.380 |
Why?
|
| Contraceptive Agents, Female | 2 | 2025 | 25 | 0.380 |
Why?
|
| Antibodies, Viral | 3 | 2026 | 306 | 0.370 |
Why?
|
| Male | 27 | 2026 | 23409 | 0.370 |
Why?
|
| Primary Prevention | 1 | 2012 | 63 | 0.370 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 449 | 0.360 |
Why?
|
| Young Adult | 14 | 2025 | 5080 | 0.340 |
Why?
|
| Quality of Life | 1 | 2015 | 616 | 0.330 |
Why?
|
| RNA, Viral | 10 | 2019 | 321 | 0.330 |
Why?
|
| Saquinavir | 2 | 2007 | 3 | 0.320 |
Why?
|
| T-Lymphocytes | 2 | 2015 | 386 | 0.310 |
Why?
|
| Infant | 7 | 2025 | 1175 | 0.310 |
Why?
|
| HIV Protease Inhibitors | 2 | 2015 | 24 | 0.310 |
Why?
|
| Contraceptive Devices, Female | 3 | 2025 | 4 | 0.310 |
Why?
|
| Emotions | 1 | 2012 | 254 | 0.300 |
Why?
|
| Viral Load | 10 | 2019 | 348 | 0.300 |
Why?
|
| Adolescent | 14 | 2019 | 6081 | 0.300 |
Why?
|
| Education, Public Health Professional | 1 | 2009 | 19 | 0.300 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 989 | 0.290 |
Why?
|
| HIV Fusion Inhibitors | 2 | 2008 | 5 | 0.290 |
Why?
|
| Cyclohexanes | 2 | 2008 | 30 | 0.290 |
Why?
|
| HIV Seropositivity | 3 | 2010 | 196 | 0.280 |
Why?
|
| Health Services Research | 1 | 2009 | 161 | 0.280 |
Why?
|
| Triazoles | 2 | 2008 | 102 | 0.270 |
Why?
|
| Vagina | 3 | 2025 | 89 | 0.270 |
Why?
|
| Mentors | 1 | 2009 | 145 | 0.270 |
Why?
|
| Ethinyl Estradiol | 2 | 2025 | 11 | 0.270 |
Why?
|
| Research Personnel | 1 | 2009 | 206 | 0.260 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2007 | 3 | 0.260 |
Why?
|
| Middle Aged | 20 | 2026 | 12222 | 0.260 |
Why?
|
| Cohort Studies | 9 | 2025 | 1759 | 0.260 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2007 | 43 | 0.250 |
Why?
|
| Pregnancy Trimester, Second | 3 | 2019 | 15 | 0.240 |
Why?
|
| Mouth | 1 | 2026 | 54 | 0.240 |
Why?
|
| Lymphocyte Subsets | 1 | 2015 | 21 | 0.230 |
Why?
|
| Antibodies, Neutralizing | 1 | 2026 | 127 | 0.230 |
Why?
|
| Family Planning Services | 1 | 2025 | 34 | 0.230 |
Why?
|
| Neoplasms | 1 | 2016 | 1377 | 0.230 |
Why?
|
| Vaccination | 2 | 2026 | 355 | 0.220 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2011 | 226 | 0.220 |
Why?
|
| Education | 1 | 2005 | 60 | 0.220 |
Why?
|
| Influenza, Human | 1 | 2015 | 92 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2025 | 83 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2025 | 88 | 0.210 |
Why?
|
| Survivors | 1 | 2005 | 152 | 0.200 |
Why?
|
| Dogs | 1 | 2024 | 204 | 0.200 |
Why?
|
| Minority Groups | 1 | 2009 | 690 | 0.200 |
Why?
|
| Mental Health Services | 1 | 2025 | 141 | 0.200 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2025 | 192 | 0.200 |
Why?
|
| Immune Tolerance | 1 | 2013 | 68 | 0.190 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 74 | 0.190 |
Why?
|
| HIV Antigens | 2 | 2008 | 5 | 0.180 |
Why?
|
| Health Status Disparities | 1 | 2009 | 719 | 0.180 |
Why?
|
| CD4 Lymphocyte Count | 7 | 2010 | 201 | 0.180 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2007 | 367 | 0.180 |
Why?
|
| Cross-Sectional Studies | 5 | 2025 | 3156 | 0.180 |
Why?
|
| Mental Disorders | 1 | 2025 | 392 | 0.170 |
Why?
|
| Lynestrenol | 1 | 2019 | 1 | 0.160 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 706 | 0.160 |
Why?
|
| Nicaragua | 1 | 2019 | 8 | 0.150 |
Why?
|
| Contraceptive Agents | 1 | 2019 | 13 | 0.150 |
Why?
|
| Guatemala | 1 | 2019 | 22 | 0.150 |
Why?
|
| Pregnancy Trimester, First | 1 | 2019 | 20 | 0.150 |
Why?
|
| Colombia | 1 | 2019 | 31 | 0.150 |
Why?
|
| Peru | 1 | 2019 | 41 | 0.150 |
Why?
|
| Brazil | 1 | 2019 | 84 | 0.150 |
Why?
|
| Language Development | 1 | 2019 | 29 | 0.150 |
Why?
|
| Drug Therapy, Combination | 4 | 2010 | 234 | 0.150 |
Why?
|
| Premature Birth | 2 | 2019 | 95 | 0.150 |
Why?
|
| Immunoglobulin M | 1 | 2019 | 86 | 0.150 |
Why?
|
| Eye Abnormalities | 1 | 2018 | 7 | 0.150 |
Why?
|
| Fetal Growth Retardation | 1 | 2019 | 53 | 0.150 |
Why?
|
| Attitude to Health | 3 | 2013 | 338 | 0.150 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2018 | 41 | 0.140 |
Why?
|
| Child Development | 1 | 2019 | 99 | 0.140 |
Why?
|
| Child | 2 | 2024 | 3443 | 0.140 |
Why?
|
| Pre-Eclampsia | 1 | 2019 | 67 | 0.140 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2023 | 40 | 0.140 |
Why?
|
| Gels | 4 | 2019 | 45 | 0.140 |
Why?
|
| Relief Work | 1 | 2017 | 6 | 0.140 |
Why?
|
| HIV | 3 | 2007 | 100 | 0.130 |
Why?
|
| Substance-Related Disorders | 1 | 2025 | 830 | 0.130 |
Why?
|
| Calcinosis | 1 | 2017 | 62 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2018 | 341 | 0.130 |
Why?
|
| Obstetrics | 1 | 2017 | 43 | 0.130 |
Why?
|
| Rectum | 1 | 2017 | 27 | 0.130 |
Why?
|
| Qualitative Research | 2 | 2021 | 574 | 0.130 |
Why?
|
| Antiviral Agents | 2 | 2017 | 195 | 0.130 |
Why?
|
| Pyridazines | 1 | 2016 | 16 | 0.130 |
Why?
|
| Double-Blind Method | 4 | 2011 | 317 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2017 | 1604 | 0.120 |
Why?
|
| Sexual Behavior | 6 | 2017 | 638 | 0.120 |
Why?
|
| Love | 1 | 2015 | 6 | 0.120 |
Why?
|
| Anti-Retroviral Agents | 3 | 2015 | 160 | 0.120 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2006 | 44 | 0.120 |
Why?
|
| Nitriles | 2 | 2016 | 81 | 0.120 |
Why?
|
| Longitudinal Studies | 4 | 2026 | 1063 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 587 | 0.110 |
Why?
|
| Pyrimidines | 2 | 2016 | 139 | 0.110 |
Why?
|
| Administration, Rectal | 3 | 2019 | 18 | 0.110 |
Why?
|
| Social Justice | 2 | 2018 | 65 | 0.110 |
Why?
|
| Vaccines, Synthetic | 2 | 2026 | 80 | 0.110 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2017 | 229 | 0.110 |
Why?
|
| United States | 5 | 2025 | 5205 | 0.100 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 2 | 0.100 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 259 | 0.100 |
Why?
|
| Cyclopropanes | 3 | 2020 | 46 | 0.100 |
Why?
|
| Alkynes | 3 | 2020 | 52 | 0.100 |
Why?
|
| Culture | 2 | 2013 | 172 | 0.100 |
Why?
|
| Patient Compliance | 2 | 2005 | 233 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 1723 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2018 | 2544 | 0.100 |
Why?
|
| Occupational Diseases | 1 | 2013 | 53 | 0.100 |
Why?
|
| Flow Cytometry | 2 | 2015 | 411 | 0.100 |
Why?
|
| Oligopeptides | 1 | 2013 | 109 | 0.100 |
Why?
|
| Pyridines | 1 | 2013 | 139 | 0.090 |
Why?
|
| Caribbean Region | 1 | 2012 | 79 | 0.090 |
Why?
|
| Down Syndrome | 1 | 2011 | 32 | 0.090 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2016 | 11 | 0.090 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2011 | 35 | 0.090 |
Why?
|
| Patient Selection | 1 | 2013 | 205 | 0.090 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 1234 | 0.090 |
Why?
|
| Area Under Curve | 3 | 2015 | 95 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2012 | 518 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 56 | 0.080 |
Why?
|
| Delivery, Obstetric | 3 | 2006 | 48 | 0.080 |
Why?
|
| Perinatal Care | 2 | 2008 | 14 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2010 | 91 | 0.080 |
Why?
|
| Risk Factors | 6 | 2012 | 3994 | 0.080 |
Why?
|
| Drug Interactions | 2 | 2020 | 150 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2015 | 661 | 0.070 |
Why?
|
| Models, Educational | 1 | 2009 | 46 | 0.070 |
Why?
|
| Genotype | 3 | 2020 | 800 | 0.070 |
Why?
|
| Immunity, Cellular | 2 | 2008 | 74 | 0.070 |
Why?
|
| Psychometrics | 1 | 2010 | 358 | 0.070 |
Why?
|
| Homosexuality, Male | 3 | 2019 | 486 | 0.070 |
Why?
|
| Herpesvirus 2, Human | 1 | 2008 | 10 | 0.070 |
Why?
|
| Herpes Genitalis | 1 | 2008 | 7 | 0.070 |
Why?
|
| Virus Shedding | 2 | 2025 | 9 | 0.070 |
Why?
|
| Drug Administration Schedule | 3 | 2016 | 153 | 0.070 |
Why?
|
| Lamivudine | 1 | 2007 | 22 | 0.070 |
Why?
|
| Cultural Competency | 1 | 2009 | 138 | 0.070 |
Why?
|
| Drug Resistance, Viral | 3 | 2010 | 67 | 0.070 |
Why?
|
| Postpartum Period | 2 | 2015 | 92 | 0.070 |
Why?
|
| Prevalence | 3 | 2025 | 1612 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2012 | 502 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2017 | 260 | 0.060 |
Why?
|
| Cooperative Behavior | 1 | 2009 | 269 | 0.060 |
Why?
|
| Animals | 1 | 2024 | 16992 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2007 | 245 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2007 | 359 | 0.060 |
Why?
|
| Prenatal Care | 1 | 2007 | 93 | 0.060 |
Why?
|
| Puerperal Disorders | 1 | 2006 | 16 | 0.060 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2008 | 174 | 0.060 |
Why?
|
| Central America | 1 | 2025 | 13 | 0.060 |
Why?
|
| South America | 1 | 2025 | 24 | 0.060 |
Why?
|
| Schools, Medical | 1 | 2007 | 208 | 0.060 |
Why?
|
| Boston | 1 | 2025 | 32 | 0.060 |
Why?
|
| Massachusetts | 1 | 2025 | 35 | 0.060 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2026 | 203 | 0.060 |
Why?
|
| Papillomaviridae | 1 | 2006 | 142 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2005 | 54 | 0.060 |
Why?
|
| Vaginosis, Bacterial | 1 | 2025 | 8 | 0.060 |
Why?
|
| Medication Adherence | 2 | 2017 | 182 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 590 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2026 | 259 | 0.060 |
Why?
|
| Cognition Disorders | 1 | 2006 | 243 | 0.050 |
Why?
|
| Mothers | 1 | 2007 | 215 | 0.050 |
Why?
|
| Aged | 3 | 2026 | 8214 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2015 | 269 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 189 | 0.050 |
Why?
|
| Electroencephalography | 1 | 2025 | 139 | 0.050 |
Why?
|
| Fetal Weight | 1 | 2023 | 9 | 0.050 |
Why?
|
| Fetal Development | 1 | 2023 | 34 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2026 | 719 | 0.050 |
Why?
|
| Women's Health | 1 | 2004 | 160 | 0.050 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2013 | 8 | 0.050 |
Why?
|
| Zidovudine | 1 | 2003 | 32 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2013 | 57 | 0.050 |
Why?
|
| Bacteria | 1 | 2026 | 293 | 0.050 |
Why?
|
| Genitalia, Female | 1 | 2003 | 29 | 0.050 |
Why?
|
| Sexual Partners | 2 | 2017 | 326 | 0.050 |
Why?
|
| Adenoviridae Infections | 1 | 2012 | 5 | 0.050 |
Why?
|
| Circumcision, Male | 1 | 2012 | 8 | 0.050 |
Why?
|
| Mass Screening | 1 | 2007 | 541 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2012 | 62 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2006 | 376 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2012 | 165 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2005 | 549 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2008 | 587 | 0.040 |
Why?
|
| Time Factors | 2 | 2012 | 1857 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 118 | 0.040 |
Why?
|
| Pharmacogenetics | 1 | 2020 | 67 | 0.040 |
Why?
|
| Reproductive Rights | 1 | 2018 | 2 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2020 | 201 | 0.040 |
Why?
|
| DNA, Viral | 3 | 2006 | 311 | 0.040 |
Why?
|
| Progesterone | 1 | 2019 | 121 | 0.040 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2008 | 7 | 0.040 |
Why?
|
| Transaminases | 1 | 2008 | 8 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 61 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2008 | 60 | 0.040 |
Why?
|
| Hepatitis B | 1 | 2008 | 41 | 0.040 |
Why?
|
| Receptors, CCR5 | 1 | 2008 | 64 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 310 | 0.040 |
Why?
|
| Survival Analysis | 3 | 2004 | 368 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2013 | 1546 | 0.040 |
Why?
|
| Lubricants | 1 | 2017 | 4 | 0.030 |
Why?
|
| Disease Progression | 3 | 2006 | 667 | 0.030 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2005 | 568 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2018 | 161 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2018 | 175 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 115 | 0.030 |
Why?
|
| Hepatitis C | 1 | 2008 | 139 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 375 | 0.030 |
Why?
|
| Glycerol | 1 | 2017 | 34 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2008 | 307 | 0.030 |
Why?
|
| Mutation | 2 | 2011 | 1177 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 863 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2006 | 490 | 0.030 |
Why?
|
| Infant, Premature | 2 | 2005 | 134 | 0.030 |
Why?
|
| HIV Seroprevalence | 1 | 2013 | 11 | 0.030 |
Why?
|
| Dominican Republic | 1 | 2013 | 20 | 0.030 |
Why?
|
| Bilirubin | 1 | 2013 | 18 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2013 | 29 | 0.020 |
Why?
|
| Informed Consent | 1 | 2013 | 35 | 0.020 |
Why?
|
| Plasma | 1 | 2013 | 38 | 0.020 |
Why?
|
| Haiti | 1 | 2013 | 86 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2005 | 638 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 497 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 287 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2008 | 1285 | 0.020 |
Why?
|
| Pregnancy Trimesters | 1 | 2011 | 15 | 0.020 |
Why?
|
| Nucleotides | 1 | 2011 | 37 | 0.020 |
Why?
|
| Adenine | 1 | 2011 | 46 | 0.020 |
Why?
|
| Nucleosides | 1 | 2011 | 30 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2011 | 38 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2013 | 457 | 0.020 |
Why?
|
| Smoking | 2 | 2006 | 1024 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 30 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2007 | 35 | 0.020 |
Why?
|
| Creatinine | 1 | 2007 | 102 | 0.020 |
Why?
|
| Wechsler Scales | 1 | 2006 | 7 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 1028 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 138 | 0.020 |
Why?
|
| Triplets | 1 | 2005 | 3 | 0.010 |
Why?
|
| Twins | 1 | 2005 | 19 | 0.010 |
Why?
|
| Comorbidity | 1 | 2008 | 737 | 0.010 |
Why?
|
| Cesarean Section | 1 | 2005 | 63 | 0.010 |
Why?
|
| Memory | 1 | 2006 | 174 | 0.010 |
Why?
|
| Parturition | 1 | 2005 | 22 | 0.010 |
Why?
|
| Self Disclosure | 1 | 2005 | 44 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 162 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2008 | 863 | 0.010 |
Why?
|
| Poisson Distribution | 1 | 2004 | 44 | 0.010 |
Why?
|
| Gestational Age | 1 | 2005 | 200 | 0.010 |
Why?
|
| Labor, Obstetric | 1 | 2004 | 16 | 0.010 |
Why?
|
| Half-Life | 1 | 2004 | 63 | 0.010 |
Why?
|
| Gravidity | 1 | 2003 | 3 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2004 | 104 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 575 | 0.010 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2004 | 129 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 2003 | 48 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 1154 | 0.010 |
Why?
|
| Incidence | 1 | 2004 | 1078 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2003 | 1067 | 0.010 |
Why?
|